Clinical Trials · NCT03555994
A Study to Investigate the Effect of MEDI0382 on Hepatic Glycogen Metabolism in Overweight and Obese Subjects With Type 2 Diabetes Mellitus.
- Phase
- Phase 2
- Recruitment status
- Completed
- Sponsor
- MedImmune LLC
- Enrollment
- 51
- Start date
- May 2018
- Locations
- 3 sites, 3 countries
- Primary endpoint
- Change in Hepatic Glycogen Concentration Adjusted for Liver Volume as Measured by MRS at T = 4 Hours Post Standardised Morning Meal From Baseline (Day -1) to the End of 28 Days of Treatment (Part A Only)